controlledtrialofadultsinMexico. Vaccine 29,7826–7834(2011). 10.1128/JVI.01693-18(2019).
demic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo- implicationforpotencytestingandimmuneprocessing. JVirol.https://doi.org/
44. López-Macías,C.etal.Safetyandimmunogenicityofavirus-likeparticlepan- 72. An, Y. et al. N-glycosylation of seasonal influenza vaccine hemagglutinins:
Influenza-Vaccinology-Report.pdf.AccessedAugust2021. glycansinviralevolutionandvaccinedesign. Sci.Transl.Med. 2,24ra21(2010).
obamawhitehouse.archives.gov/sites/default/files/microsites/ostp/PCAST- 71. Wei,C.J.etal.Cross-neutralizationof1918and2009influenzaviruses:roleof
enterprisetomeetthechallengesofpandemicinfluenza.Availableathttps:// influenzavaccine:evidencefromamousemodel. J.Med.Virol. 72,138–142(2004).
43. Report to the president on reengeneering the influenza vaccine production 70. Babiuk,S.etal.AggregatecontentinfluencestheTh1/Th2immuneresponseto
27,33(2020). (2002).
42. Chen,J.R.etal.Betterinfluenzavaccines:anindustryperspective. J.Biomed.Sci. passive surveillance, Canada 2001-2002. Can. Commun. Dis. Rep. 28, 189–196
Hum.VaccinImmunother. 11,1209–1222(2015). 69. Choudhri,Y.&Walop,W.Influenzavaccine-associatedadverseevents:resultsof
41. Xiang, K. et al. Progress on adenovirus-vectored universal influenza vaccines. sonsinCanada. Can.Commun.Dis.Rep. 31,217–225(2005).
opingthenextgenerationofinfluenzavaccines. Vaccines 8,574(2020). vaccination:reviewofpost-marketing surveillance throughfourinfluenza sea-
40. Sayedahmed, E. E. etal.Adenoviral vector-based vaccine platforms for devel- 68. PublicHealthAgencyofCanada.Oculo-respiratorysyndromefollowinginfluenza
vaccine. PLoSONE 7,e33428–e33428(2012). 10.3390/vaccines6020031(2018).
nogenicityandprotectionconferredwithanadenovirus-basedH5N1influenza virus and within vaccines using electron microscopy. Vaccines https://doi.org/
39. Pandey,A.etal.Impactofpreexistingadenovirusvectorimmunityonimmu- 67. Gallagher, J. R. et al. Characterization of hemagglutinin antigens on influenza
8028–8038(2018). tionofinfluenzavirusvaccine. Hum.VaccinesImmunother. 11,1673–1684(2015).
derived virus-like particles bearing influenza hemagglutinin. Vaccine 36, 66. Tay,T.etal.Investigationintoalternativetestingmethodologiesforcharacteriza-
38. Won, S. Y. et al. Characterization of the innate stimulatory capacity of plant- dependentantibodyresponsesinhumans. NPJVaccines 5,77(2020).
1491–1503(2020). unit vaccines in elicitation of influenza-specific CD4 T cells and CD4 T cell-
adults (>/=65 years): two multicentre, randomised phase 3 trials. Lancet 396, 65. Richards,K.A.etal.RecombinantHA-basedvaccineoutperformssplitandsub-
rivalent, virus-like particle influenza vaccine in adults (18-64 years) and older 8,99(2020).
37. Ward,B.J.etal.Efficacy,immunogenicity,andsafetyofaplant-derived,quad- neutralizingantibodiesagainststructurallydistinctdomainsofH3N2HA. Vaccines
18to49and>/=50yearsoldadults. PLoSONE 14,e0216533(2019). 64. Portnoff,A.D.etal.Influenzahemagglutininnanoparticlevaccineelicitsbroadly
likeparticleinfluenzavaccinecandidate-tworandomizedPhaseIIclinicaltrialsin hemagglutininfusionmachineryoninfluenzavirions. Sci.Adv. 6,eaaz8822(2020).
36. Pillet,S.etal.Immunogenicityandsafetyofaquadrivalentplant-derivedvirus 63. Benhaim, M. A. etal. Structural monitoring of a transient intermediate in the
Immunol. 168,72–87(2016). allinfluenzaAsubtypes. Cell 166,596–608(2016).
induces cross-reactive antibody and T cell response in healthy adults. Clin. 62. Kallewaard,N.L.etal.Structureandfunctionanalysisofanantibodyrecognizing
35. Pillet,S.etal.Aplant-derivedquadrivalentviruslikeparticleinfluenzavaccine epitope. Science 324,246–251(2009).
fightagainstCOVID-19? Vaccines 8,183(2020). 61. Ekiert, D. C. et al. Antibody recognition of a highly conserved influenza virus
34. Rosales-Mendoza,S.etal.Whatdoesplant-basedvaccinetechnologyoffertothe differentinfluenzavaccineplatformsinhumans. Nat.Commun. 10,3338(2019).
expressedin Escherichiacoli. Gene 21,273–284(1983). 60. Khurana,S.etal.Repeatvaccinationreducesantibodyaffinitymaturationacross
33. Davis, A. R. et al. Immune response to human influenza virus hemagglutinin e3000139(2019).
bacteria. ActaBiochimPol. 61,561–572(2014). separation of hemagglutinin receptor-binding head domains. PLoS Biol. 17,
32. Saczynska, V.Influenzavirus hemagglutinin asavaccine antigen produced in 59. Turner,H.L.etal.Potentanti-influenzaH7humanmonoclonalantibodyinduces
producedin Escherichiacoli. PLoSONE 5,e11694(2010). (2015).
31. Aguilar-Yanez, J. M. et al. An influenza A/H1N1/2009 hemagglutinin vaccine broadly cross-reactive antibodies. Curr. Top. Microbiol. Immunol. 386, 323–341
proteins. OpenForumInfect.Dis. 3,ofw015(2016). 58. Lee,P.S.&Wilson,I.A.Structuralcharacterizationofviralepitopesrecognizedby
seasonal flu vaccine comprising recombinant hemagglutinin-flagellin fusion (1983).
30. Tussey, L. et al. Phase 1 safety and immunogenicity study of a quadrivalent hemagglutininmoleculeofH3influenzavirusatacidicpH. Virology 126,587–599
ONE 3,e2257(2008). 57. Webster,R.G.,Brown,L.E.&Jackson,D.C.Changesintheantigenicityofthe
bacterial expression: a solution to global pandemic and seasonal needs. PLoS insectandmammaliancells. Curr.Opin.Biotechnol. 10,428–433(1999).
29. Song,L.etal.Efficaciousrecombinantinfluenzavaccinesproducedbyhighyield 56. Kost,T.A.&Condreay,J.P.Recombinantbaculovirusesasexpressionvectorsfor
1560-7917.Es.2017.22.13.30494(2017). revealsstructuralpolymorphisms. Clin.Vaccin.Immunol. 23,483–495(2016).
sibles = European communicable disease bulletin 22, https://doi.org/10.2807/ hemagglutinin complexes by cryo-electron microscopy and image analyses
visiontoreality.Eurosurveillance:bulletinEuropeensurlesmaladiestransmis- 55. McCraw,D.M.,Gallagher,J.R.&Harris,A.K.Characterizationofinfluenzavaccine
28. Shu,Y.&McCauley,J.GISAID:Globalinitiativeonsharingallinfluenzadata-from perspective. AnnuRev.Biophys. 47,153–173(2018).
167–171(2017). 54. Boonstra, S. et al. Hemagglutinin-mediated membrane fusion: a biophysical
effectiveness-UnitedStates,February2017. MMWRMorb.Mortal.WklyRep. 66, 406–430(2015).
27. Flannery, B. et al. Interim estimates of 2016-17 seasonal influenza vaccine enza: the role of the haemagglutinin cleavage site motif. Rev. Med Virol. 25,
NatlAcad.Sci.USA 114,12578–12583(2017). 53. Luczo,J.M.etal.MolecularpathogenesisofH5highlypathogenicavianinflu-
thataltersbindingofantibodieselicitedbyegg-adaptedvaccinestrains. Proc. 95,409–417(1998).
26. Zost,S.J.etal.ContemporaryH3N2influenzaviruseshaveaglycosylationsite minantofinfluenzapathogenicityandtheoriginofthelabileconformation. Cell
circulatingviruses. PLoSONE 9,e92153(2014). 52. Chen,J.etal.Structureofthehemagglutininprecursorcleavagesite,adeter-
with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in (1992).PMC556715.
25. Skowronski,D.M.etal.Low2012-13influenzavaccineeffectivenessassociated siteisactivatedbyfurin,asubtilisin-likeendoprotease. EMBOJ. 11,2407–2414
egg-adaptedvaccinestrain. Nat.Med. 22,1465–1469(2016). 51. Stieneke-Gröber,A.etal.Influenzavirushemagglutininwithmultibasiccleavage
24. Raymond,D.D.etal.Influenzaimmunizationelicitsantibodiesspecificforan laughingmatter. Proc.NatlAcad.Sci.USA 95,9713–9715(1998).
cells. J.Invertebr.Pathol. 107,S31–S41(2011). 50. Taubenberger, J.K.Influenzavirus hemagglutinin cleavageintoHA1,HA2:no
23. Cox,M.M.&Hashimoto,Y.Afasttrackinfluenzavirusvaccineproducedininsect sed19April2021.
10,702–714(2015). drug-products/applications-submissions/register-innovative-drugs.html. Acces-
manufacturingplatformforviralvaccinesandgenetherapyvectors. Biotechnol.J. from https://www.canada.ca/en/health-canada/services/drugs-health-products/
22. Felberbaum, R. S. The baculovirus expression vector system: a commercial 49. HealthCanada.RegisterofInnovativeDrugs[Updated15April2021].Available
Med. 121,S22–S27(2008). February2021.
duction,distribution,supply,anddemand–whatitmeansfortheprovider. Am.J. assessment-report/supemtek-epar-public-assessment-report_en.pdf. Accessed 17
21. Orenstein,W.A.&Schaffner,W.Lessonslearned:roleofinfluenzavaccinepro- EMEA/H/C/005159/0000. Available at https://www.ema.europa.eu/en/documents/
placebo-controlledphaseItrial. Nat.Med. 27,106–114(2021). 48. European Medicines Agency. Assessment report. Supemtek. Procedure No.
vaccine approach induces broad and long-lasting immunity in a randomized, 2021.
20. Nachbagauer,R.etal.Achimerichemagglutinin-baseduniversalinfluenzavirus azureedge.net/media/documents/VAC_infl_publ_rpt_10-07.pdf. Accessed August
vaccine:differentapproachesforonegoal. Virol.J. 15,17(2018). 47. Influenza vaccine strategies for broad global access. Available at https://path.
19. Sautto, G. A., Kirchenbaum, G. A. & Ross, T. M. Towards a universal influenza particles. ExpertRev.Vaccines 12,225–236(2013).
(2018). 46. Fernandes,F.etal.Insectcellsasaproductionplatformofcomplexvirus-like
definedbyavaccine-inducedantibody. Proc.NatlAcad.Sci.USA 115,168–173 ticlevaccine. Biopharm.Int 23Suppl10,26–34(2010).